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frequencies were available. Shares of testers by therapies (OAD/INSULIN) were
10.0% and 21.8%. Physicians recommended an average of 5.9 tests per week, pa-
tients performed 2.8 (47.5%). For OAD/INSULIN test-frequencies were 2.8 and 2.2.
Doctors rated the SMBG adherence as good or very good in 43% of cases.
CONCLUSIONS: In community centers the vast majority of patients have type 2
diabetes. FPG values were broadly documented, but the therapy quality marker
HbA1 is only available for the minority of patients. SMBG was more common with
insulin users, but clearly below guideline recommendations. It needs to be deter-
mined which measures could potentially improve the current practice in diabetes
care in order to strengthen the role of community health centers in managing the
diabetes epidemic in China.
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FAILURE FOR COST-SHARING SCHEMES TO TAKE OFF IN INDIA: WHAT CAN BE
THE ACCESS SOLUTION?
Kirpekar S
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OBJECTIVES:With high costs of some oncology and biological therapies, manufac-
turers have introduced patient access schemes in Asian countries including Indo-
nesia,Malaysia, Philippines andChinawhere the out-of-pocket is themain funding
and access mechanism. These schemes have been welcomed by stakeholders in-
volved including patients, clinicians and governments. Our objectivewas to under-
stand why such programmes have not succeeded in India despite a large middle
class and almost complete out-of-pocket funding for pharmaceuticals, and to find
possible ways to overcome the hurdles presented. METHODS: The approach in-
volved desk research followed by primary research across stakeholders in India.
Twelve in-depth telephone interviews were conducted with stakeholders in the
public and private sectors, NGOs, leading physicians and manufacturers. The in-
formation collected was assessed and analysed. RESULTS:Majority of the respon-
dents (n10) quoted bureaucracy and the informal economy, and thus difficulties
with means-testing as the twomost important reasons for the schemes not taking
up. General ignorance about the potential of such schemes and cynicism surround-
ing them are a deterrent. Unethical medical practice, a great patient – provider
knowledge gap and a lack of streamlined infrastructure for scheme delivery are
thought to be important factors. Respondents confirmed that majority of the large
middle class lacks access to innovative medicines for many diseases. The Gleevec
patient access scheme was quoted by a few respondents as a rare example of such
a scheme being run. Partnering with the public sector and NGOs was thought to be
an alternative way out. There was mention of many local NGOs/charities which
fund targeted oncology therapies for those with limited resources. CONCLUSIONS:
India needs tailored, innovative ways of accessing high cost drugs for its local
context being different from those in other countries in the region. Public-private
partnerships involving large stakeholders such as theMinistry of Railways could be
an option.
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OBJECTIVES: Access to medications is one of the main goals of Iran National Drug
Policy (NDP). Being a function of multifactors such as distribution of pharmacies, if
the geographical access is observed, drug accessibility is gauranteed to some ex-
tent. The aim of this study is to compare the Geographical distribution of pharma-
cies versus population in two capital cities of Iran. METHODS: Two cities of Iran
with strategical and transitional importance with cultural and socioeconomical
differences (Khorramabad and Ahwaz) were selected. In the first step the popula-
tion of different regions was collected from state government databases. Further-
more all of the pharmacies’ locations in these two cities were detected through
their Food andDrug deputies. The percent of population and pharmacies located in
each region were calculated and compared together by differentiating relatad per-
cents inorder to find an overview of present status of distribution and access to
pharmacies. RESULTS: Ahwaz and Khorramabad, twowest-southern cities of Iran,
with a population of approximately 1,000,000 and 5200,000 are seperated to eight
and three regions respectively. Unlike Khorramabad, an even distribution of pop-
ulation was found in Ahwaz. The differences in percent of population versus phar-
macies in order from first to eighth region of Ahwaz were found as followed: 13.8,
3.9, -4, -8.3, 6.1, -2.6, -5.6 and -3.3. Those of the three regions of Khorramabad were
-18, 17 and 1. CONCLUSIONS: The results show the distribution of pharmacies in
both cities does not match that of population in most regions. However in one
region of Khorramabad and three regions of Ahwaz the distribution was accept-
able. This can be justified by the fact that physicians are mostly concentrated in
few regions that attract the pharmacists. It should be noted that the suitablity of
population and pharmcies’ distribution is one of the most important factors in
evaluating access to medicine.
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OBJECTIVES: Chronic disease has become a major problem affecting the health of
the Chinese population. In response to this situation, the New Rural Cooperative
Medical Scheme (NRCMS) has begun to provide health cover for outpatients with
chronic disease expenses, made possible by the increased risk pool of recent years.
We compared the differences between benefit packages for chronic disease outpa-
tients in 32 counties, in order to assess their population reach, equity and cost
implications and to formulate recommendations for policy makers. METHODS:
Information on the various benefit packages was located by searching the official
NRCMS websites in Chinese at the end of 2009. We developed a conceptual frame-
work based on the three main criteria: 1) population coverage; 2) service coverage;
and 3) costs with various subcriteris to compare benefit packages in 32 counties
across China. Chronic diseases were classified according to the ICD-10. RESULTS:
With the intention of avoiding “moral hazard” county NRCMS offices have devel-
oped complex processes to define benefit packages for chronic diseases. These
have resulted in substantial differences in benefit package equity and cost between
counties. In most counties chronic disease patients find it very difficult to become
beneficiaries. Forty-one chronic diseaseswere identified in the 32 counties, varying
between 4 and 28 per individual county. We also found large discrepancies in
co-payment rates, deductibles, ceilings, coverage of drugs and tests, accredited
hospitals and reimbursement frequency. CONCLUSIONS: Reimbursement proce-
dures are remarkably diverse in different counties. Population coverage, service
coverage and cost of benefit packages for chronic diseases vary substantially in the
32 counties studied. This reflects the new policy of decentralization of decision
making to the county-level resulting in a “postcode lottery” of patient benefits.
National regulation to redress these inefficiencies and inequities is urgently
needed.
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OBJECTIVES: To evaluate health insurance coverage rate among poor and disad-
vantaged citizens and study the cause and condition of not being involved in health
insurance. METHODS: The sampling size was estimated by using the number of
poor and needy in selected districts. By using multistage–sampling method, con-
centration of poor and poverty group among the total person of selected districts
were calculated. There are sampling size at 5% sampling error (d5%), confidence
interval (CI95%) and the influence of non-sampling error estimated. RESULTS: In
the first years of health insurance in Mongolia, there was coverage achieved at
96-97%, but later it decreased because of diversity of employment‘s structure, in-
creasing unemployment rate, and most influential factor as PHC was excluded
from social health insurance. The result shows, HI coverage was 95.3% in 1998, but
this rate was decreased till 84.4% in 2008. 95-97% of people who were involved in
the survey, have lower income than living standard. According to the pattern of
age, majority includes 26-35 aged economic hummers and as of gender, there were
44.79 % male and 55.21% female. To survey whether all people who were involved
in the survey, got covered by health insurance last 3 years, there were 47.14% of
them involved in health insurance. As forms of paying insurance fee, 17.3% paid
insurance fee by voluntary, 49.17% paid by government and 33.7% paid by mixed
forms. To survey on the health insurance coverage during the survey, 42.4% were
involved. As forms of paying insurance fee, 27.61% paid by voluntary, 41.1% paid by
mixed. CONCLUSIONS: The health insurance cannot protect poor and disadvan-
taged citizens from financial and other risks. People cannot be provided by equal
and sufficient health services because of health insurance non-involvement,
breach of citizenship identification paper and no registration of citizenship. The
main reason of health insurance non-involvement depends on economic disad-
vantage and lack of information.
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OBJECTIVES: The implementation of the New Rural Cooperative Medical Scheme
(NRCMS) has been spreading fast since a county pilot trial began in September 2003.
The purpose of this survey was to guide policy makers of Huxian county and ulti-
mately improve the current national NRCMS policy. METHODS: Cross-sectional
survey of the attitudes of farmers towards the NRCMS conducted in 2005. A total of
1978 farmers living in 50 villages in Huxian Shaanxi Province were surveyed using
a door-to-door questionnaire. The survey asked farmers questions regarding their
awareness of the NRCMS and their opinions of the scheme, including methods of
reimbursement and raising funds and concerns regarding the scheme’s
sustainability.RESULTS:Most farmers hold a positive attitude towards theNRCMS.
There are issues, however, in regard to the farmers’ trust in the scheme and pre-
ferred payment methods. Farmers place more trust in village doctors rather than
village cadres for fund collection.More than two thirds of farmers visit county-level
hospitals directly when they require inpatient treatment. Not all hospitals and
doctors fully comply with the NRCMS rules, and supplier-induced demand is still
widespread. More than half the farmers stated that they worry that the NRCMS is
unable to be sustained. Importantly the survey showed a high enrolment rate of
92% (95% CI, 91; 93) in a voluntary insurance scheme. CONCLUSIONS: Despite a
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high voluntary enrolment rate in the NRCMS a number of issues have been iden-
tified in the survey. Three key remedial actions in health financing, planning and
management to counteract the identified issues are proposed: 1) Enacting legisla-
tion and setting up a risk fund to ensure sustainability of the NRCMS; 2)The main
rights and responsibilities of related parties in the NRCMS should be clarified to
improve the incentive mechanism; and 3) Integrate disease prevention and the
reform of township hospitals.
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OBJECTIVES: To estimate the incidences of hospitalizations for statin-related ad-
verse events (AEs) and further evaluate the influence of the concomitant use of
fibrates or cytochrome P450 (CYP) 3A4 inhibitors on the risks of AEs in patients
initiating statin treatments. METHODS: A retrospective cohort study design was
employed with analyses from the Taiwan National Health Insurance Research Da-
tabase between January 1, 2000 and December 31, 2007. The study cohort com-
prised patients initially treated with statins, and was followed to observe the oc-
currence of hospitalizations for statin-associated AEs, including myopathy, renal
adverse events, hepatotoxic events and acute pancreatitis. Use of statins was fur-
ther categorized into three groups to examine the effect of concomitant use of the
interacting drugs: statin-fibrate combination, statin-CYP3A4 inhibitor combina-
tion, and statin monotherapy. Poisson regressions were used to estimate the indi-
vidual incidences and incidence rate ratios (IRRs) of hospitalization events for the
combined therapies versus statin monotherapy. RESULTS: A total of 53,594 statin
initiators were identified as the study cohort, with atorvastatin and lovastatin
being observed as the most commonly prescribed statins. The proportion of statin
initiators concomitantly treated with fibrates and CYP3A4 inhibitors was 7.1% and
14.3%, respectively. Overall, the highest incidence occurred in renal adverse events
(36.8/10,000 person-years), followed by hepatotoxic events, acute pancreatitis, and
myopathy. A similar ranking order of the incidences was observed across the three
groups. Compared to statin monotherapy, combination therapy of statins with the
interacting medications increased the risks of overall AEs (statin-fibrate combina-
tion: adjusted IRR, 2.01; 95% CI, 1.21-3.32; statin-CYP3A4 inhibitor combination:
adjusted IRR, 2.29; 95% CI, 1.73-3.02). CONCLUSIONS: Renal toxicity is found to be
the most frequently occurring AE during statin treatments. Concomitant use of
statins with fibrates or CYP3A4 inhibitors increases the risks of statin-associated
AEs, which warrants caution for close monitoring of adverse symptoms when st-
atins are used concurrently with the potential interacting drugs.
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OBJECTIVES: To evaluate the association between use of antipsychotics and risk of
stroke in patients with cardiovascular diseases (CVDs).METHODS: This was a ret-
rospective nested case-control study analyzing data from the National Health In-
surance Research Database in Taiwan. A cohort of all patients with CVDs initiating
an antipsychotic was identified during January 1, 1998 and December 31, 2006.
Cases were defined as those with hospitalizations for stroke (ICD9-CM codes 430-
438, A-code A29), and the date of stroke admission was referred as the index date.
Using the incidence density sampling approach, each case was matched to ten
randomly-selected controls on age ( 5 years), sex and cohort entry date ( 365
days). Controlswere assigned the same index date as their corresponding case. Use
of antipsychotics was measured during a six-month period before the index date
and categorized into typical or atypical class. Conditional logistic regressions were
used to estimate odds ratios (ORs).RESULTS:The study cohort comprised 6773 CVD
patients, fromwhich 533 cases and 5057matched controls were identified. Any use
of atypical antipsychotics was associated with an increased risk of stroke when
compared with typical antipsychotics (adjusted OR, 1.46; 95 % CI, 1.01-2.10). Addi-
tionally, the comparative risk was increased to a greater extent as atypical antip-
sychotics were prescribed within 90 days before the index date (adjusted OR, 1.94;
95% CI, 1.34-2.83). Further stratified analyses indicated that any use of atypical
antipsychotics was associated with a 1.55-fold increased risk of stroke in the el-
derly population. CONCLUSIONS: Use of atypical antipsychotics is associated with
an increased risk of stroke relative to typical antipsychotics among patients with
CVDs, and the risk is further increased as atypical antipsychotics are prescribed
more currently. Clinicians should be aware of the stroke risk while prescribing
antipsychotics for patients with underlying CVDs, especially in the elderly.
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OBJECTIVES: To determine the outcome and the prognostic factors among severe
sepsis and septic shock (SS&SK) survivors one year after hospital discharge.
METHODS: This was a retrospective and cross-sectional study of patients (18
years) admitted 24 hours between April 2007 and March 2010 for the first time to
themedical-surgical and trauma intensive care unit (ICU) of a tertiary hospital and
discharged from the hospital alive. For patients withmore than one ICU admission
within the same hospitalization, only first ICU admission was counted. Data ob-
tained from an electronic ICU database, hospital information system and medical
records. Additionally, We conducted telephonic interviews to evaluate vital status
and performance at one year of hospital discharge using KARNOFSKY PERFOR-
MANCE STATUS SCALE. Patients who had cardiac arrest were excluded from the
study. RESULTS: The overall mortality rate was 35%. One-third (31%) of who were
still survive at one year post hospital discharge, suffer from significant (P0.05)
impairment of performance status. SS&SK survivors who had CHF had 3.4 times
higher risk to die as compared to who did not had CHF. Pre-sepsis performance
status and CHF were the independent prognostic factors for poor hospital out-
comes on long term post hospital discharge in SS&SK survivors. CONCLUSIONS:
About one third of patients die by one year, another one-third suffer from signifi-
cant impairment of performance status. Pre-sepsis performance status and CHF
were the independent prognostic factors in SS&SK survivors. This data highlights
the need for different strategies for caring of SS&SK survivors.
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OBJECTIVES: Thrombolytic therapy is widely accepted as a standard treatment for
patients diagnosed with ST-Elevated Acute Coronary Syndrome (ACS). Enoxaparin
has been the most commonly used medicine but its increased risk of bleeding is a
major concern. Fondaparinux has been available with a potentially better safety
profile, but there still no direct head to head study comparing these two agents.
This study aims to determine the comparative efficacy and safety of enoxaparin
and fondaparinux for treating ST-Elevated ACS using a network meta-analysis.
METHODS:We undertook a systematic review to identify studies from computer-
ized databases including Pubmed, Cochrane and Clinical Trial.gov. Inclusion crite-
ria are 1) RCT in STEMI patients receiving fibrinolytic agent, and 2) Using Enoxa-
parin or Fondaparinux. Efficacy outcome was death or myocardial re-infarction at
30 days, while safety outcome wasmajor bleeding event during in hospital or at 30
days. All studies were extracted independently by 2 reviewers. Heterogeneity was
tested using Q-statistics and I2 test. Indirect comparison based on a networkmeta-
analysis under a random-effects model was used to synthesize the comparison
between these 2 products. RESULTS: Seven studies were included in this study (6
compared Enoxaparin and UFH and 1 Compared Fondaparinux and UFH). The re-
sult of network meta-analysis indicated similar efficacy between fondaparinux
and enoxaparin (OR  1.12 (CI: 0.76-1.65), with the lower risk of major bleeding in
the fondaparinux group (OR  0.40 (CI: 0.17-0.96). There was no heterogeneity
revealed from Q-statistics and I2. CONCLUSIONS: Our study indicated that among
patients with STEACS receiving fibrinolytic agent, fondaparinux has similar effi-
cacy on death/myocardial infarction but statistically significant lower bleeding
event compared with enoxaparin. Fondaparinux seems to have favorable risk/
benefit profile compared with Enoxaparin when used in STEMI patients receiving
fibrinolytic agents.
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OBJECTIVES: Statins are the first-line drug therapy in the treatment of hypercho-
lesterolemia. The beneficial clinicalimpact of statins on the cardiovascular system
resultsnot only from their lipid-lowering action but also from their pleiotropic
effects. Recently, it has been suggested thatstatins can reduce blood pressure;
however the available data are still ambiguousand often conflicting. Therefore we
performed the meta-analysis to investigate the potential hypotensive action of
statins in patients with or without hypertension. METHODS: Data from Scopus,
PubMed,Web of Science, and the Cochrane Central Register of Controlled Trials for
years 1966 to October 2011 were searched for studies that investigated the effect of
statins on blood pressure either in normotensive or hypertensive subjects.
RESULTS: Finally themeta-analysis included 18 trials - 5628 subjects (4692 normo-
tensive, 936 hypertensive) randomized to receive either statins or placebo.The
standardized effect size of mean differences of systolic (DSBP) and diastolic blood
pressure (DDBP) in normotensive patients for ten included trials for statins therapy
was 0.006 (95%CI: -0.052-0.063; p0.84) and -0.03 (95%CI: -0.09-0.03; p0.3), respec-
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